Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Common Equity: 2011-2025

Historic Common Equity for Mimedx Group (MDXG) over the last 14 years, with Sep 2025 value amounting to $238.9 million.

  • Mimedx Group's Common Equity rose 32.01% to $238.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.9 million, marking a year-over-year increase of 32.01%. This contributed to the annual value of $193.1 million for FY2024, which is 35.31% up from last year.
  • According to the latest figures from Q3 2025, Mimedx Group's Common Equity is $238.9 million, which was up 10.30% from $216.6 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx Group's Common Equity peaked at $238.9 million during Q3 2025, and registered a low of -$19.5 million during Q3 2022.
  • Over the past 3 years, Mimedx Group's median Common Equity value was $168.0 million (recorded in 2024), while the average stood at $133.6 million.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 22,036.59% in 2022, then soared by 13,509.62% in 2024.
  • Quarterly analysis of 5 years shows Mimedx Group's Common Equity stood at $82,000 in 2021, then slumped by 22,036.59% to -$18.0 million in 2022, then soared by 893.40% to $142.7 million in 2023, then soared by 35.31% to $193.1 million in 2024, then surged by 32.01% to $238.9 million in 2025.
  • Its last three reported values are $238.9 million in Q3 2025, $216.6 million for Q2 2025, and $202.8 million during Q1 2025.